Gadoteridol

Gadoteridol
Clinical data
Other names	(10-(2-(hydroxy-κO)propyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3−)-κN1,κN4,κN7,κN10,κO1,κO4,κO7)-gadolinium
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Routes of; administration	IV
ATC code	V08CA04 (WHO) ;
Legal status
Legal status	CA: ℞-only; US: WARNINGRx-only;
Identifiers
	IUPAC name gadolinium(+3) cation; 2-[4-(2-hydroxypropyl)-7,10-bis(2-oxido-2-oxoethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;
CAS Number	120066-54-8 ;
PubChem CID	60714;
DrugBank	DB00597 ;
ChemSpider	54719 ;
UNII	0199MV609F;
KEGG	D01137 ;
ChEBI	CHEBI:31643 ;
ChEMBL	ChEMBL1200593 ;
CompTox Dashboard (EPA)	DTXSID2048662 ;
Chemical and physical data
Formula	C17H29GdN4O7
Molar mass	558.69 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [Gd+3].[O-]C(=O)CN1CCN(CCN(CCN(CC(O)C)CC1)CC([O-])=O)CC([O-])=O;
	InChI InChI=1S/C17H32N4O7.Gd/c1-14(22)10-18-2-4-19(11-15(23)24)6-8-21(13-17(27)28)9-7-20(5-3-18)12-16(25)26;/h14,22H,2-13H2,1H3,(H,23,24)(H,25,26)(H,27,28);/q;+3/p-3 ; Key:DPNNNPAKRZOSMO-UHFFFAOYSA-K ;
	(what is this?) (verify)

Gadoteridol (INN) is a gadolinium-based MRI contrast agent, used particularly in the imaging of the central nervous system. It is sold under the brand name ProHance.^[3] Gadoteridol was first approved for use in the United States in 1992.^[4]

References

^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
^ "Prohance Product information". Health Canada. 30 July 1998. Retrieved 19 April 2024.
^ Bracco Diagnostic Inc. (26 October 2022). "Gadoteridol (ProHance) prescribing information". DailyMed. U.S. National Library of Medicine. Retrieved 17 May 2023.
^ Morgan DE, Spann JS, Lockhart ME, Winningham B, Bolus DN (April 2011). "Assessment of adverse reaction rates during gadoteridol-enhanced MR imaging in 28,078 patients". Radiology. 259 (1): 109–16. doi:10.1148/radiol.10100906. PMID 21248237. Specifically, the rate of nausea (0.530%) was less than half the rate (1.4%) in clinical trials of 1251 patients, leading to FDA approval in 1992.